Inhibition of endogenous HIF inactivation induces angiogenesis in ischaemic skeletal muscles of mice

被引:132
作者
Milkiewicz, M [1 ]
Pugh, CW [1 ]
Egginton, S [1 ]
机构
[1] Univ Birmingham, Dept Physiol, Birmingham B15 2TT, W Midlands, England
来源
JOURNAL OF PHYSIOLOGY-LONDON | 2004年 / 560卷 / 01期
关键词
D O I
10.1113/jphysiol.2004.069757
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Hypoxia-inducible factor (HIF) modulates transcriptional control of several genes involved in vascular growth and cellular metabolism. HIF activity can be enhanced by suppression of prolyl and asparaginyl hydroxylase activity by dimethyloxalylglycine (DMOG). We have compared the effects of DMOG treatment and femoral artery ligation individually or in combination on HIF-1alpha protein level, HIF-dependent gene expression and cappillary-to-fibre ratio (C: F) in extensor digitorum longus and tibialis anterior muscles of mice. Immuno-histochemical examination revealed that HIF-1alpha is present in non-ischaemic mouse skeletal muscles, but its amount increased profoundly in response to the combination of DMOG treatment and ischaemia. Combined treatment resulted in 39% increase in C:F in ischaemic muscles (P < 0.0001 versus controls) whereas individual treatments produced little effect under our conditions. Combined treatment led to a significant increase in endogenous HIF-1alpha protein (6.14 +/- 1.1 versus 1.17 +/- 0.2 in controls; P < 0.05) that was not apparent in mice treated with DMOG or femoral artery ligation alone. Ischaemia increased vascular endothelial growth factor (VEGF) protein production by 2.5-fold (P < 0.05 versus controls), irrespective of DMOG treatment. However, production of the VEGF receptor Flk-1 was more enhanced in ischaemic + DMOG-treated muscles (P < 0.001 and P < 0.05 compared with controls and untreated ischaemic muscles, respectively), which may explain the intensive growth of capillaries in those muscles. The findings indicate that treatment with DMOG has a potential therapeutic use in promoting angiogenesis in ischaemic diseases, and perhaps for improving muscle recovery after injury, exercise or training.
引用
收藏
页码:21 / 26
页数:6
相关论文
共 19 条
[1]   Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor [J].
Baumgartner, I ;
Rauh, G ;
Pieczek, A ;
Wuensch, D ;
Magner, M ;
Kearney, M ;
Schainfeld, R ;
Isner, JM .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (11) :880-884
[2]   Transcription - Oxygen sensing gets a second wind [J].
Bruick, RK ;
McKnight, SL .
SCIENCE, 2002, 295 (5556) :807-808
[3]   Angiogenesis in health and disease [J].
Carmeliet, P .
NATURE MEDICINE, 2003, 9 (06) :653-660
[4]   Re-evaluating therapeutic neovascularization [J].
de Muinck, ED ;
Simons, M .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2004, 36 (01) :25-32
[5]   Cooperative interaction of hypoxia-inducible factor-2α (HIF-2α) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1) [J].
Elvert, G ;
Kappel, A ;
Heidenreich, R ;
Englmeier, U ;
Lanz, S ;
Acker, T ;
Rauter, M ;
Plate, K ;
Sieweke, M ;
Breier, G ;
Flamme, I .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (09) :7520-7530
[6]   Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation [J].
Jaakkola, P ;
Mole, DR ;
Tian, YM ;
Wilson, MI ;
Gielbert, J ;
Gaskell, SJ ;
von Kriegsheim, A ;
Hebestreit, HF ;
Mukherji, M ;
Schofield, CJ ;
Maxwell, PH ;
Pugh, CW ;
Ratcliffe, PJ .
SCIENCE, 2001, 292 (5516) :468-472
[7]  
Kim JH, 2002, J CERAM PROCESS RES, V3, P25
[8]   PR39, a peptide regulator of angiogenesis [J].
Li, J ;
Post, M ;
Volk, R ;
Gao, Y ;
Li, M ;
Metais, C ;
Sato, K ;
Tsai, J ;
Aird, W ;
Rosenberg, RD ;
Hampton, TG ;
Li, JY ;
Sellke, F ;
Carmeliet, P ;
Simons, M .
NATURE MEDICINE, 2000, 6 (01) :49-55
[9]   Differential expression of Flk-I and Flt-I in rat skeletal muscle in response to chronic ischaemia: favourable effect of muscle activity [J].
Milkiewicz, M ;
Hudlicka, O ;
Verhaeg, J ;
Egginton, S ;
Brown, MD .
CLINICAL SCIENCE, 2003, 105 (04) :473-482
[10]   2-oxoglutarate analogue inhibitors of HIF prolyl hydroxylase [J].
Mole, DR ;
Schlemminger, I ;
McNeill, LA ;
Hewitson, KS ;
Pugh, CW ;
Ratcliffe, PJ ;
Schofield, CJ .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (16) :2677-2680